Lilly's Foundayo Shows 57% Mortality Reduction in Landmark ACHIEVE-4 Diabetes Trial

Key Takeaways

• Foundayo achieved 57% reduction in all-cause mortality and 16% lower MACE-4 events compared to insulin glargine in the longest Phase 3 study to date
• The drug met its primary non-inferiority endpoint while showing superior cardiovascular safety profile for type 2 diabetes patients
• Eli Lilly plans FDA submission by end of Q2 2024, potentially bringing a breakthrough diabetes treatment to market

---

Eli Lilly Reports Breakthrough Results for Foundayo in Type 2 Diabetes

Eli Lilly and Company announced positive results from ACHIEVE-4, the longest Phase 3 clinical trial of its investigational diabetes drug Foundayo (orforglipron) to date. The study demonstrated that Foundayo not only met its primary safety objective but also showed remarkable cardiovascular benefits, including a 57% reduction in all-cause mortality compared to insulin glargine.

Superior Cardiovascular Outcomes Drive Clinical Success

In the ACHIEVE-4 trial, Foundayo successfully achieved non-inferiority versus insulin glargine while delivering superior cardiovascular outcomes. The drug showed a 16% lower risk of MACE-4 (Major Adverse Cardiovascular Events) and a 23% lower risk of MACE-3 events compared to the standard insulin treatment.

The most striking finding came from a pre-planned analysis revealing that patients treated with Foundayo had a 57% lower risk of death from any cause compared to those receiving insulin glargine. This substantial mortality benefit suggests Foundayo could offer more comprehensive health advantages beyond glucose control for type 2 diabetes patients.

Market Impact and Regulatory Timeline

The positive ACHIEVE-4 results position Foundayo as a potential game-changer in the competitive diabetes therapeutics market. With over 37 million Americans living with diabetes, according to the CDC, effective treatments with proven cardiovascular benefits represent significant commercial opportunities.

Based on these compelling trial results, Lilly plans to submit a New Drug Application (NDA) for Foundayo to the U.S. Food and Drug Administration by the end of the second quarter of 2024. This aggressive timeline reflects the company’s confidence in the drug’s regulatory prospects and commercial potential.

Competitive Landscape and Clinical Significance

Foundayo enters a crowded but lucrative diabetes treatment market that includes established therapies like GLP-1 receptor agonists and SGLT-2 inhibitors. However, the drug’s demonstrated cardiovascular benefits and mortality reduction could differentiate it from existing options.

The cardiovascular safety profile is particularly important given that diabetes patients face elevated risks of heart disease and stroke. Current treatment guidelines emphasize the importance of diabetes medications that provide cardiovascular protection, making Foundayo’s profile especially attractive to healthcare providers.

Investment and Development Implications

The ACHIEVE-4 results represent a significant milestone for Lilly’s diabetes portfolio and could drive substantial shareholder value. Successful diabetes drugs with cardiovascular benefits have historically achieved blockbuster status, with annual sales exceeding $1 billion.

For patients, Foundayo’s profile suggests a potential new treatment option that addresses both glucose control and cardiovascular risk reduction. The 57% mortality benefit, if confirmed in regulatory review, could make Foundayo a preferred treatment choice for many type 2 diabetes patients.

Looking Ahead

As Lilly prepares its FDA submission, the pharmaceutical industry will closely watch the regulatory review process. The drug’s strong efficacy and safety profile in ACHIEVE-4 provides a solid foundation for approval, though regulatory outcomes remain uncertain until FDA review is complete.

The success of ACHIEVE-4 also validates Lilly’s broader diabetes research strategy and could accelerate development of related compounds in the company’s pipeline. For the diabetes community, Foundayo represents hope for improved treatment outcomes and better long-term health prospects.

---

Frequently Asked Questions

What does Foundayo’s 57% mortality reduction mean for diabetes patients?

The 57% reduction in all-cause mortality suggests Foundayo could significantly extend life expectancy for type 2 diabetes patients compared to standard insulin treatment, though individual results may vary and the drug requires FDA approval first.

When will Foundayo be available for patients?

Lilly plans to submit Foundayo to the FDA by end of Q2 2024. If approved, the drug could potentially reach patients in 2025, though exact timing depends on the FDA review process which typically takes 6-12 months.

How does Foundayo compare to existing diabetes treatments like Ozempic or Jardiance?

While direct comparisons weren’t made in ACHIEVE-4, Foundayo’s 57% mortality reduction and superior cardiovascular outcomes versus insulin glargine suggest it could be highly competitive with current leading diabetes therapies, pending head-to-head studies.

IntelligenceRegulatory Impact▾

FDA are the agencies to watch. Regulatory relevance reads medium for type 2 diabetes with cardiovascular benefits, with Foundayo (orforglipron) and insulin glargine most exposed to upcoming decisions. Teams should track submission types, designations, and guidance shifts that could move approval timelines.

Related profiles

• insulin glargine

Related coverage

• Breast Cancer Statistics Worldwide: What the Data Shows
• Obesity rates in America by year: what the data shows
• BioNTech doses first patient in Phase 1 pancreatic cancer mRNA vaccine trial